Lista de obras -

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes

artículo científico publicado en 2011

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

artículo científico publicado en 2010

Bone mineral density and prevalent vertebral fractures in men and women

artículo científico publicado en 2003

Circulating sclerostin associated with vertebral bone marrow fat in older men but not women

artículo científico publicado en 2014

Does a history of non-vertebral fracture identify women without osteoporosis for treatment?

artículo científico publicado en 2008

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

artículo científico publicado en 2009

Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial

article

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

artículo científico

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

artículo científico publicado en 2010

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

artículo científico publicado en 2006

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study

artículo científico publicado en 2014

Fracture risk in diabetic elderly men: the MrOS study

artículo científico publicado en 2014

Long-term risk of incident vertebral fractures

artículo científico publicado en 2007

Lumbar spine listhesis in older African American women

artículo científico publicado en 2003

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial

artículo científico publicado en 2011

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

artículo científico publicado en 2005

Prediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures.

artículo científico publicado en 2014

Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans

artículo científico publicado en 2012

Prevalent vertebral fractures in black women and white women

artículo científico publicado en 2008

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

artículo científico publicado en 2014

Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study

artículo científico publicado en 2015

Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures

article by Michael C Nevitt et al published January 2005 in Journal of Bone and Mineral Research

Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures

artículo científico publicado en 2004

Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures

artículo científico publicado en 2013

Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial

artículo científico publicado en 2012

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

artículo científico publicado en 2003

Thiazolidinedione use and bone loss in older diabetic adults

artículo científico publicado en 2006

Use of Alendronate After 5 Years of Treatment—Reply

artículo científico publicado en 2007

Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults

artículo científico publicado en 2013

Lista de obras de

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Bone mineral density and prevalent vertebral fractures in men and women

Circulating sclerostin associated with vertebral bone marrow fat in older men but not women

Does a history of non-vertebral fracture identify women without osteoporosis for treatment?

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study

Fracture risk in diabetic elderly men: the MrOS study

Long-term risk of incident vertebral fractures

Lumbar spine listhesis in older African American women

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

Prediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures.

Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans

Prevalent vertebral fractures in black women and white women

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study

Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures

Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures

Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures

Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

Thiazolidinedione use and bone loss in older diabetic adults

Use of Alendronate After 5 Years of Treatment—Reply

Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults

What Proportion of Incident Radiographic Vertebral Deformities Is Clinically Diagnosed and Vice Versa?